Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Managed Health Care2.03%-0.53 ppHealth Care Services0.66%-0.25 ppPharmaceuticals5.26%+0.22 ppLife Sciences Tools & Services1.77%-0.21 ppHealth Care Equipment2.95%+0.09 ppHealth Care Supplies0.20%+0.04 ppHealth Care Facilities0.24%+0.04 ppBiotechnology2.41%+0.02 ppHealth Care Distributors0.39%-0.01 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.41%
Industry change · 12M
+0.02 pp
Biotechnology · contribution
+0.016 pp
Company participation
88%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Aug 2023 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals → REGN | United States | $77.7bn | 0.247% | +0.077 pp | +0.052 pp | +42.2% | Yes |
| Moderna → MRNA | United States | $43.0bn | 0.137% | +0.017 pp | -0.048 pp | -14.5% | No |
| Vertex Pharmaceuticals → VRTX | United States | $89.9bn | 0.287% | +0.081 pp | +0.028 pp | +23.6% | Yes |
| AbbVie → ABBV | United States | $259.4bn | 0.827% | +0.225 pp | -0.024 pp | +13.7% | Yes |
| Amgen → AMGN | United States | $137.1bn | 0.437% | +0.146 pp | -0.023 pp | +10.3% | Yes |
| Biogen → BIIB | United States | $38.7bn | 0.123% | +0.017 pp | +0.022 pp | +36.8% | Yes |
| Gilead Sciences → GILD | United States | $95.3bn | 0.304% | +0.067 pp | +0.019 pp | +25.2% | Yes |
| Incyte → INCY | United States | $14.5bn | 0.046% | +0.012 pp | -0.010 pp | -8.4% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.